Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine?

Colombel, Jean–Frédéric; Brabant, G.; Gubler, Marie–Claire; Locquet, A; Comes, Marie-Christine; Dehennault, Maud; Delcroix, M.

doi:10.1016/s0140-6736(94)92009-5

Cited by 77 publications

(35 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infant stool patterns should therefore be monitored if the mother is using mesalamine for IBD therapy and is breastfeeding [19] . There is a general preference for clinicians in limiting limiting the maximum dose to 2 g mesalamine daily during pregnancy based on an association with neonatal renal insufficiency in a 1994 report [85] . This dose is low compared to the normal non-pregnant patient maximum dose of 2.4 to 4.8 g daily depending on the preparation being used.…”

Section: Aminosalicylatesmentioning

confidence: 99%

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Hosseini‐Carroll¹,

Mutyala²,

Seth³

et al. 2015

WJGPT

View full text Add to dashboard Cite

Manas K made critical revisions of the manuscript; Becker F and Alexander JS contributed equally as senior authors. Conflict-of-interest statement:There are no known conflicts of interest. The authors (Pegah Hosseini-Carroll, Monica Mutyala, Abhishek Seth, Shaheen Nageeb, Demiana Soliman, Moheb Boktor, Ankur Sheth, Jonathon Chapman, James Morris, Paul Jordan, Kenneth Manas, Felix Becker, and J Steven Alexander) have no relevant financial considerations related to this proposal, and the study was not supported by any corporate entity. There is no known intellectual property associated with this report. AbstractInflammatory bowel diseases (IBD) are chronic idiopathic inflammatory conditions characterized by relapsing and remitting episodes of inflammation which can affect several different regions of the gastrointestinal tract, but also shows extra-intestinal manifestations. IBD is most frequently diagnosed during peak female reproductive years, with 25% of women with IBD conceiving after their diagnosis. While IBD therapy has improved dramatically with enhanced surveillance and more abundant and powerful treatment options, IBD disease can have important effects on pregnancy and presents several challenges for maintaining optimal outcomes for mothers with IBD and the developing fetus/neonate. Women with IBD, the medical team treating them (both gastroenterologists and obstetricians/gynecologists) must often make highly complicated choices regarding conception, pregnancy, and post-natal care (particularly breastfeeding) related to their choice of treatment options at different phases of pregnancy as well as post-partum. This current review discusses current concerns and recommendations for pregnancy during 157November 6, 2015|Volume 6|Issue 4| WJGPT|www.wjgnet.com Hosseini-Carroll P et al . Pregnancy and inflammatory bowel diseases IBD and is intended for gastroenterologists, general practitioners and IBD patients intending to become, (or already) pregnant, and their families. We have addressed patterns of IBD inheritance, effects of IBD on fertility and conception (in both men and women), the effects of IBD disease activity on maintenance of pregnancy and outcomes, risks of diagnostic procedures during pregnancy and potential risks and complications associated with different classes of IBD therapeutics. We also have evaluated the clinical experience using "top-down" care with biologics, which is currently the standard care at our institution. Post-partum care and breastfeeding recommendations are also addressed. Core tip: Inflammatory bowel diseases (IBD) are chronic inflammatory conditions characterized by relapsing and remitting episodes of intestinal inflammation. IBD is most frequently diagnosed during peak female reproductive years, with 25% of women with IBD conceiving after their diagnosis. While therapies have improved dramatically, IBDs have important effects on pregnancy and present challenges for maintaining optimal outcomes for mothers and their developing fetus/ neonate. Women with IBD and physician...

show abstract

Section: Aminosalicylatesmentioning

confidence: 99%

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Hosseini‐Carroll¹,

Mutyala²,

Seth³

et al. 2015

WJGPT

View full text Add to dashboard Cite

show abstract

“…[66]. Some providers advocate a maximum of 2 g a day of mesalamine during pregnancy, which may be based on a 1994 case report of oral mesalamine being associated with neonatal renal insufficiency [67]. However, this finding has not been replicated in several large-scale studies [29,41,46,48].…”

Section: Medicationsmentioning

confidence: 99%

Management of inflammatory bowel disease in pregnancy

Ng¹,

2013

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

“…However, some previous reports have described potential teratogenicity for this drug (19,30,42) . There are some studies that describe neonatal jaundice with SZA (17,58) . The replacement of folic acid is recommended because of the antagonistic effects of SSZ, interacting with the cell membrane transporters.…”

Section: A) Aminossalicilatesmentioning

confidence: 99%

“…The mesalazine (MZA) in conventional doses is safe during pregnancy (21) and in higher doses (above 3 g/d) at risk of developing interstitial nephritis in newborn (17) but without teratogenicity (17,21,38) . It is also considered Class B drug for use during the pregnancy.…”

Section: A) Aminossalicilatesmentioning

confidence: 99%

Treatment of inflammatory bowel disease and pregnancy: a review of the literature

Correia

Bonilha

Ramos

et al. 2010

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -The inflammatory bowel disease is diagnosed frequently among woman of childbearing capacity. The management must be carefully because there are potential risks for the mother and fetus. Results and conclusions -We review literature about the management of inflammatory bowel disease in pregnancy. Some studies are needed to ensure the best approach to inflammatory bowel disease in pregnant women. HEADINGS -Inflammatory bowel disease. Pregnancy complications, infectious. Infliximab.

show abstract

Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine?

Cited by 77 publications

References 3 publications

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management

Management of inflammatory bowel disease in pregnancy

Treatment of inflammatory bowel disease and pregnancy: a review of the literature

Contact Info

Product

Resources

About